| 发明名称 |
Specifikke anti-CD160-antilegemer for behandling af øjensygdomme på grundlag af neoangiogenese |
| 摘要 |
The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM 1-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases. |
| 申请公布号 |
DK2575881(T3) |
申请公布日期 |
2017.01.09 |
| 申请号 |
DK20110728594T |
申请日期 |
2011.05.27 |
| 申请人 |
INSERM - Institut National de la Santé et de la Recherche Médicale;Elsalys Biotech |
发明人 |
LE BOUTEILLER, Philippe;BENSUSSAN, Armand |
| 分类号 |
A61K39/00;A61K9/00;A61K39/395;A61P27/02;C07K16/22;C07K16/28 |
主分类号 |
A61K39/00 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
|
| 地址 |
|
